Xenon Files Azetukalner NDA and Pulls MDD Data Date

The Tip Desk · November 12, 2026 · 3 min read

Cash, cash equivalents and marketable securities were $1.15 billion as of September 30, 2026, with a net loss of $110.4 million for the quarter.

Xenon Pharmaceuticals Inc. (XENE), a neuroscience-focused biopharmaceutical company, submitted a New Drug Application for azetukalner in focal seizures to the U.S. Food and Drug Administration in September 2026, completing the filing it had said in the prior quarter was on track for the third quarter after a pre-NDA meeting.

The company also completed enrollment in the Phase 3 X-NOVA2 study of azetukalner in major depressive disorder with about 360 patients and moved the expected topline data readout to December 2026, from the first-half 2027 date it had given while enrollment was still ongoing. In September it announced a voluntary pause on new patient enrollment in ongoing Phase 3 azetukalner studies in MDD and bipolar depression; patients already enrolled, including open-label extensions, remain active.

President and Chief Executive Officer Ian Mortimer said the company had made significant progress advancing azetukalner with the NDA submission and through scientific exchange, and that it continues to have confidence in the drug’s epilepsy profile based on efficacy and safety across more than 1,500 patient-years of data. He said the company is working toward its first Phase 3 psychiatry data readout with topline results now expected in December 2026.

Xenon presented six abstracts at the 16th European Epilepsy Congress in September, including an encore oral presentation of X-TOLE2 topline efficacy and safety data. It expects additional azetukalner and epilepsy presentations at the American Epilepsy Society annual meeting December 4–8 in Denver. The Phase 3 X-TOLE3 study in focal seizures continues to enroll and is intended to support regulatory submissions outside the United States, with enrollment outside Japan expected to complete in 2026. The Phase 3 X-ACKT study in primary generalized tonic-clonic seizures also continues to enroll. The company plans to initiate X-FIRST, a new Phase 3b/4 study of azetukalner as a first adjunctive antiseizure medication in focal seizures, in the first quarter of 2027.

At the IASP 2026 World Congress on Pain in October, Xenon presented positive Phase 1 single- and multiple-ascending-dose data for XEN1701, a NaV1.7 candidate, and XEN1120, a KV7 candidate. XEN1701 achieved the company’s target profile, including high NaV1.7 receptor occupancy in the peripheral and central nervous system, and was generally well-tolerated with no notable autonomic cardiovascular effects. XEN1120 achieved plasma levels predictive of analgesic effects based on preclinical modeling and was generally well-tolerated. Based on those results, Xenon expects to initiate Phase 2 proof-of-concept studies in acute pain for both candidates in the first half of 2027. A Phase 1 study of XEN1720, a second NaV1.7 candidate, is ongoing.

Cash, cash equivalents and marketable securities were $1,153.5 million as of September 30, 2026, compared with $586.0 million as of December 31, 2025. Based on current operating plans, Xenon anticipates sufficient cash to fund operations into 2029. Common shares outstanding were 98,275,278, with 1,507,885 pre-funded warrants.

Research and development expenses were $95.6 million for the three months ended September 30, 2026, compared with $77.1 million a year earlier. The company said the increase was primarily attributable to ongoing azetukalner Phase 3 studies in MDD and bipolar depression, manufacturing to support potential commercialization and launch readiness, the XEN1720 Phase 1 study, and higher personnel-related costs including stock-based compensation. General and administrative expenses were $24.4 million, compared with $19.3 million, from higher personnel costs, stock-based compensation, and professional and consulting fees. Other income was $11.5 million, compared with $6.1 million, primarily from higher interest income.

Net loss was $110.4 million, or $1.11 a share, for the quarter, compared with $90.9 million, or $1.15 a share, a year earlier. The company said the wider loss was primarily attributable to higher research and development expenses driven by the azetukalner and pain programs and higher personnel-related costs, higher general and administrative expenses, partially offset by higher interest income. Revenue remained zero.